Se-cure Pharmaceuticals Inc., is a subsidiary company of Se-cure Pharmaceuticals Ltd., a research-driven biotech company focused on the discovery and development of therapeutic solutions originating from botanical sources with an emphasis on safety of use.
Se-cure develops unique botanical solutions that integrate the pharmaceutical world with the dietary supplement world, balancing them both to create highly effective solutions that can be taken for the long term, improving quality of life without incurring risks.
Se-cure has a state-of-the-art pharmaceutical manufacturing facility operating under rigorous quality control standards, producing standardized nutraceuticals with swift efficacy and the highest standards of safety. We are dedicated to bringing forth unique botanical solutions that provide relief of symptoms while avoiding the risks of conventional options.
Se-cure manufactures the products developed in-house in a state-of-the-art, pharmaceutical-grade manufacturing facility operating under rigorous quality control standards. The manufacturing procedure of Brizo® follows the highest industry standards. Comprehensive microbiological and biochemical testing are rigorously performed throughout the process. We are committed to making each and every capsule identical in its therapeutic characteristics within the accepted standards.
Brizo® was launched in 2011 and provides optimal support for prostate health in men. Brizo® offers a completely fresh approach to the management of urinary frequency and urgency in men, providing swift results, without exposure to risks. With Brizo® the quality of life is regained without undesirable side effects.
Our team is dedicated to creating supplements that provide proven relief of symptoms while avoiding risks.
We are dedicated to the highest levels of scientific excellence and commit our research to provide safe and effective options for consumers and healthcare professionals.
The Femarelle® Line supports women in the different stages of estrogen decline, from pre-menopause through menopause and post-menopause. The Femarelle® line launched in 2000, was declared as the first line of therapy for the management of menopause, at the 2017 Annual Meeting of the European Society of Gynecology.
For more information about Femarelle visit –www.femarelle.us